Compile Data Set for Download or QSAR
Report error Found 116 Enz. Inhib. hit(s) with all data for entry = 50016011
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591423(CHEMBL5189653)
Affinity DataIC50: 0.590nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408768(US10364238, Example 77 | N-[(6-cyano-2-fluoro-3-me...)
Affinity DataIC50: 1nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM263248(US9533987, example 31 | 1-[4-(4-methyl-pyrazol-1-y...)
Affinity DataIC50: 2nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591409(CHEMBL5192089)
Affinity DataIC50: 3nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: 3.20nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528094(N-[(4-methoxy-3-methylpyridin-2-yl)methyl]-3-(meth...)
Affinity DataIC50: 4.10nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591420(CHEMBL5172353)
Affinity DataIC50: 4.40nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591401(CHEMBL5174626)
Affinity DataIC50: 4.5nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591419(CHEMBL5171646)
Affinity DataIC50: 5.10nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM497307(N-[(6-chloro-2-fluoro-3-methoxyphenyl)methyl]-3-(m...)
Affinity DataIC50: 5.5nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591421(CHEMBL5176313)
Affinity DataIC50: 5.5nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408746(US10364238, Example 66 | N-[(2,6-difluoro-3-metho...)
Affinity DataIC50: 6nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717(US10364238, Example 41 | N-[(3-fluoro-4-methoxypy...)
Affinity DataIC50: 6nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591410(CHEMBL5203063)
Affinity DataIC50: 6.30nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591412(CHEMBL5191190)
Affinity DataIC50: 6.80nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591406(CHEMBL5206249)
Affinity DataIC50: 7.80nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591417(CHEMBL5189174)
Affinity DataIC50: 7.90nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM186919(US9670157, 85 1-[4-(4-Methyl-pyrazol-1-ylmethyl)-b...)
Affinity DataIC50: 11nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408734(US10364238, Example 53 | N-[(2-fluoro-3-methoxyph...)
Affinity DataIC50: 17nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408733(US10364238, Example 52 | 3-cyclopropyl-N-[(2-fluo...)
Affinity DataIC50: 23nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591405(CHEMBL5198301)
Affinity DataIC50: 31nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408744(US10364238, Example 64 | N-[(2-fluoro-5-methoxyph...)
Affinity DataIC50: 35nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528088(N-[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]-3-(...)
Affinity DataIC50: 37nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591407(CHEMBL5172155)
Affinity DataIC50: 40nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408717(US10364238, Example 41 | N-[(3-fluoro-4-methoxypy...)
Affinity DataIC50: 54nMAssay Description:Inhibition of DXS induced human whole plasma kallikrein using H-D-Pro-Phe-Arg-AFC as substrate preincubated for 5 mins followed by DXS stimulation by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591404(CHEMBL5192676)
Affinity DataIC50: 62nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591422(CHEMBL5175689)
Affinity DataIC50: 62nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM186955(US9670157, 96 2,5-Dimethyl-1-[4-(4-methyl-pyrazol-...)
Affinity DataIC50: 65nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591408(CHEMBL5194528)
Affinity DataIC50: 68nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM186835(US9670157, 1 2,5-Dimethyl-1-(2-phenyl-thiazol-4-yl...)
Affinity DataIC50: 72nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408738(US10364238, Example 59 | 3-(dimethylamino)-N-[(2-...)
Affinity DataIC50: 73nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528084(N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-1-({4-[...)
Affinity DataIC50: 76nMAssay Description:Inhibition of DXS induced human whole plasma kallikrein using H-D-Pro-Phe-Arg-AFC as substrate preincubated for 5 mins followed by DXS stimulation by...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591403(CHEMBL5176481)
Affinity DataIC50: 88nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591402(CHEMBL5204652)
Affinity DataIC50: 90nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591416(CHEMBL5177449)
Affinity DataIC50: 93nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM186948(US9670157, 90 2,5-Dimethyl-1-[4-(2-oxo-2H-pyridin-...)
Affinity DataIC50: 110nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408794(US10364238, Example 132 | N-[(3-ethyl-2-fluorophe...)
Affinity DataIC50: 140nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528097(N-[(3-fluoro-4-methylpyridin-2-yl)methyl]-3-(metho...)
Affinity DataIC50: 140nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591411(CHEMBL5176433)
Affinity DataIC50: 150nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528092(N-[(5-chloro-3-fluoropyridin-2-yl)methyl]-3-(metho...)
Affinity DataIC50: 160nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528086(N-[(5-cyano-2-methoxypyridin-4-yl)methyl]-3-(metho...)
Affinity DataIC50: 160nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591415(CHEMBL5178736)
Affinity DataIC50: 210nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591414(CHEMBL5201841)
Affinity DataIC50: 220nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528091(N-[(5-chloro-3-cyanopyridin-2-yl)methyl]-3-(methox...)
Affinity DataIC50: 250nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528098(N-[(3-chloro-4-methylpyridin-2-yl)methyl]-3-(metho...)
Affinity DataIC50: 300nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM186842(US9670157, 8 2,5-Dimethyl-1-(5-pyridin-3-yl-thioph...)
Affinity DataIC50: 440nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408790(US10364238, Example 129 | N-[(2-fluoro-3-hydroxyph...)
Affinity DataIC50: 440nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM408711(3-(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl...)
Affinity DataIC50: 460nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM528100(N-[(5-methoxy-1-methylpyrazol-3-yl)methyl]-3-(meth...)
Affinity DataIC50: 460nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
TargetPlasma kallikrein(Human)
Kalvista Pharmaceuticals

Curated by ChEMBL
LigandPNGBDBM50591399(CHEMBL5194439)
Affinity DataIC50: 480nMAssay Description:Inhibition of human plasma kallikrein using H-D-Pro-Phe-Arg-AFC as flurogenic substrate preincubated for 5 mins followed by substrate addition by flu...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/20/2023
Entry Details
PubMed
Displayed 1 to 50 (of 116 total ) | Next | Last >>
Jump to: